HSBC Holdings’s Puma Biotechnology PBYI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-19,751
Closed -$66.6K – 3036
2025
Q2
$66.6K Sell
19,751
-758
-4% -$2.42K ﹤0.01% 2907
2025
Q1
$60.5K Buy
+20,509
New +$64.2K ﹤0.01% 2885
2022
Q4
– Sell
-18,913
Closed -$45K – 3157
2022
Q3
$45K Sell
18,913
-4,371
-19% -$12.8K ﹤0.01% 2830
2022
Q2
$66K Hold
23,284
– – ﹤0.01% 3102
2022
Q1
$71K Hold
23,284
– – ﹤0.01% 3170
2021
Q4
$71K Hold
23,284
– – ﹤0.01% 3177
2021
Q3
$163K Buy
+23,284
New +$174K ﹤0.01% 2819
2019
Q4
– Sell
-19,774
Closed -$213K – 3151
2019
Q3
$213K Buy
+19,774
New +$214K ﹤0.01% 2836
2018
Q3
– Sell
-38,018
Closed -$2.25M – 2619
2018
Q2
$2.25M Buy
+38,018
New +$2.2M ﹤0.01% 1454
2018
Q1
– Sell
-2,430
Closed -$240K – 2588
2017
Q4
$240K Buy
2,430
+445
+22% +$49.8K ﹤0.01% 1839
2017
Q3
$238K Sell
1,985
-17,178
-90% -$1.6M ﹤0.01% 2065
2017
Q2
$1.68M Buy
+19,163
New +$1.07M ﹤0.01% 1323
2015
Q4
– Sell
-5,997
Closed -$452K – 2254
2015
Q3
$452K Sell
5,997
-1,408
-19% -$133K ﹤0.01% 1439
2015
Q2
$865K Buy
+7,405
New +$1.34M ﹤0.01% 1283

Other funds holding PBYI

HSBC Holdings's PBYI Position: Q3 2025 in Review

HSBC Holdings sold out of Puma Biotechnology (PBYI) in Q3 2025, closing a stake of 19,751 shares — an estimated $66.6K sold.

HSBC Holdings first reported a position in PBYI in Q2 2015 and held it in 14 quarters. The position peaked at $2.25M in Q2 2018. 132 funds tracked by Wall St. Rank hold PBYI as of Q3 2025.

  • HSBC Holdings reported no remaining Puma Biotechnology position as of Q3 2025 after selling out during the quarter.
  • HSBC Holdings sold 19,751 Puma Biotechnology shares in Q3 2025, an estimated $66.6K.
  • HSBC Holdings first reported a position in Puma Biotechnology in Q2 2015 and held it in 14 quarters.
  • HSBC Holdings's Puma Biotechnology position peaked at $2.25M in Q2 2018.
  • 132 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2025.

Based on HSBC Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.